Results 321 to 330 of about 196,164 (338)

First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial

Lancet, The, 2017
Pascal Joly, Maud Maho-Vaillant, Sebastien Calbo   +2 more
exaly  

Rituximab

Reactions Weekly, 2014
openaire   +2 more sources

Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma

Journal of Clinical Oncology, 2006
Thomas M Habermann, Randy D Gascoyne, Richard I Fisher   +2 more
exaly  

Rituximab

Reactions Weekly, 2009
openaire   +1 more source

Rituximab

Reactions Weekly, 2020
openaire   +1 more source

Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)

Annals of the Rheumatic Diseases, 2018
P. Charles, B. Terrier, É. Perrodeau, P. Cohen, S. Faguer, A. Huart, M. Hamidou, C. Agard, B. Bonnotte, M. Samson, A. Karras, N. Jourde-Chiche, F. Lifermann, P. Gobert, C. Hanrotel-Saliou, P. Godmer, N. Martin-Silva, G. Pugnet, M. Matignon, O. Aumaître, J. Viallard, F. Maurier, N. Méaux‐Ruault, S. Riviére, J. Sibilia, X. Puéchal, P. Ravaud, L. Mouthon, L. Guillevin   +28 more
semanticscholar   +1 more source

First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial

Lancet Oncology, The, 2016
Anna-Maria Fink, Christian Maurer, Marek Trneny   +2 more
exaly  

Rituximab

Reactions Weekly, 2018
  +4 more sources

Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular Lymphoma

Journal of Clinical Oncology, 2003
Ronald Levy
exaly  

Rituximab

Reactions Weekly, 2013
openaire   +2 more sources